Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph P Fuhr

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|May 1, 2009
Biosimilars and follow-on biologicsJoseph P Fuhr
American Health & Drug Benefits|April 12, 2016
The Economics of Medicare Accountable Care OrganizationsErwin A Blackstone, Joseph P Fuhr
Journal of Health Care Finance|November 1, 2008
Specialty hospitals: the economics and policy issues they poseErwin A Blackstone, Joseph P Fuhr
Biotechnology Healthcare|May 19, 2012
Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safetyErwin A Blackstone, Joseph P Fuhr
Journal of Health Law|August 28, 2003
Failed hospital mergersErwin A Blackstone, Joseph P Fuhr
Future Medicinal Chemistry|March 25, 2011
Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticalsErwin A Blackstone, Joseph P Fuhr
Biotechnology Healthcare|February 12, 2013
Generic biopharmaceutical drugs: an economic and policy analysisErwin A Blackstone, Joseph P Fuhr
Biotechnology Healthcare|April 6, 2012
Biopharmaceuticals: the economic equationErwin A Blackstone, Joseph P Fuhr
Infection Control and Hospital Epidemiology|September 11, 2004
Cost-benefit analysis of chlorhexidine gluconate dressing in the prevention of catheter-related bloodstream infectionsAlbert G Crawford, Joseph P Fuhr, Bhaskar Rao
American Health & Drug Benefits|August 16, 2014
The health and economic effects of counterfeit drugsErwin A Blackstone, Joseph P Fuhr, Steve Pociask
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Expert Review of Pharmacoeconomics & Outcomes Research|May 1, 2009
Biosimilars and follow-on biologicsJoseph P Fuhr
American Health & Drug Benefits|April 12, 2016
The Economics of Medicare Accountable Care OrganizationsErwin A Blackstone, Joseph P Fuhr
Journal of Health Care Finance|November 1, 2008
Specialty hospitals: the economics and policy issues they poseErwin A Blackstone, Joseph P Fuhr
Biotechnology Healthcare|May 19, 2012
Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safetyErwin A Blackstone, Joseph P Fuhr
Journal of Health Law|August 28, 2003
Failed hospital mergersErwin A Blackstone, Joseph P Fuhr
Future Medicinal Chemistry|March 25, 2011
Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticalsErwin A Blackstone, Joseph P Fuhr
Biotechnology Healthcare|February 12, 2013
Generic biopharmaceutical drugs: an economic and policy analysisErwin A Blackstone, Joseph P Fuhr
Biotechnology Healthcare|April 6, 2012
Biopharmaceuticals: the economic equationErwin A Blackstone, Joseph P Fuhr
Infection Control and Hospital Epidemiology|September 11, 2004
Cost-benefit analysis of chlorhexidine gluconate dressing in the prevention of catheter-related bloodstream infectionsAlbert G Crawford, Joseph P Fuhr, Bhaskar Rao
American Health & Drug Benefits|August 16, 2014
The health and economic effects of counterfeit drugsErwin A Blackstone, Joseph P Fuhr, Steve Pociask
Pageof 2